Study of anti-liver fibrosis effect of astralosides via circular RNA34116
ZHOU Yuping1, YANG Ping2, TANG Chunlan3, QU Hui1, LYU Xueyou1, HU Guimei1
1.Department of Gastroenterology, the Affiliated Hospital of Medical School of Ningbo University, Ningbo 315020, China; 2.School of Nursing, Ningbo College of Health Sciences, Ningbo 315100, China; 3.Department of Preventive Medicine, Medical School of Ningbo University, Ningbo 315211, China
ZHOU Yuping,YANG Ping,TANG Chunlan, et al. Study of anti-liver fibrosis effect of astralosides via circular RNA34116[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2019, 49(4): 263-266.
Abstract：Objective: To study the mechanism underlying Astragalosides in the inhibition of hepatic fibrosis via circularRNA. Methods: Mice were randomly divided as normal group, CCl4 model group, Astragalosides group and sorafenib group, with 8 mice in each group. A CCl4 liver fibrosis model was established. After drug intervention with Astragalosides, the serum ALT and TBIL, pathological changes (HE staining and Masson staining) of the liver and relative mmu_circ_34116 expressionwere detected and observed by RT-PCR. Results: Histopathological results showed that, compared with the normal group, liver tissue inflammation and collagen deposition were significantly increased Astragalosides and sorafenib significantly reduced inflammation and collagen deposition. The results of serum liver function showed that Astragalosides and sorafenib significantly reduced the level of ALT and TBIL after intervention in the model mice. RT-PCR results showed that, compared with the normal group, the expression of mmu_circ_34116 in liver tissue was significantly reduced in CCl4 model group, and its expression was significantly increased after intervention with Astragalosides in the model, but sorafenib had no significant effect on its expression. Conclusion: Astragalosides significantly inhibited the development of liver fibrosis. The mechanism may be associated with over expression of mmu_circ_34116.
[1] WANG F S, FAN J G, ZHANG Z, et al. The global burden of liver disease: the major impact of China[J]. Hepatology, 2014, 60(6) : 2099-2108.
[2] 陈长喜, 杜娟, 徐益敏, 等. 中老年人非酒精性脂肪肝与糖化血红蛋白关系的流行病学研究[J]. 中华内科杂志, 2015, 54(6): 517-520.
[3] FENG R, YUAN X, SHAO C, et al. Are we any closer to treating liver fibrosis (and if no, why not)?[J]. J Dig Dis, 2018, 19(3): 118-126.
[4] LIU P. Inhibition of pathological angiogenesis of Chinese medicine against liver fibrosis[J]. Chin J Integr Med, 2016, 22(8): 569-572.
[5] 张良登, 孙晓红, 魏玮, 等. 肝纤维化中医理论源流[J]. 世界中西医结合杂志, 2014, 9(3): 300-304.
[6] 张华, 刘平. 基于黄芪汤益气效应解析代偿期乙肝肝硬化的“虚损”病机理论[J]. 世界科学技术-中医药现代化, 2016, 18(11): 1833-1838.
[7] 马红, 王宝恩, 陈翌阳, 等. 黄芪对肝纤维化治疗作用的实验研究[J]. 中华肝脏病杂志, 1997, 5(1): 32-33.
[8] 张蔷, 高文远, 满淑丽. 黄芪中有效成分药理活性的研究进展[J]. 中国中药杂志, 2012, 37(21): 3203-3207.
[9] 王文祥, 熊晓滨. AST提取物对牛血清白蛋白致大鼠肝纤维化作用的影响[J]. 中国实验方剂学杂志, 2013, 19(9): 277-280.
[10] MU Y P, ZhANG X, LI X W, et al. Astragaloside prevents BDL-induced liver fibrosis through inhibition of notch signaling activation[J]. J Ethnopharmacol, 2015, 1(169): 200-209.
[11] CHEN S, ZHAO Y. Circular RNAs: Characteristics, function, and role in human cancer. Histol Histopathol[J]. 2018, 33(9): 887-893.
[12] YAO T, CHEN Q, FU L Y, et al. Circular RNAs: Biogenesis, properties, roles, and their relationships with liver diseases [J]. Hepatol Res, 2017, 47(6): 497-504.
[13] 周玉平, 吕雪幼, 璩辉, 等. 肝纤维化模型小鼠肝组织环状RNA表达谱分析[J]. 温州医科大学学报, 2018, 48(8): 563-566.
[14] ZHOU Y, Lv X, QU H, et al. Differential expression of circular RNAs in hepatic tissue in a model of liver fibrosis and functional analysis of their target genes[J]. Hepatol Res, 2019, 49(3): 324-334.
[15] WILHELM S M, ADNANE L, NEWELL P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling[J]. Mol Cancer Ther, 2008, 7(10): 3129-3140.
[16] 王林, 李波, 耿智敏, 等. 索拉菲尼对肝星状细胞活性及活化的影响[J]. 郑州大学学报(医学版), 2014, 49(4): 501-504.
